ALTOONA — Alan Kivitz, M.D., founder of the Altoona Center for Clinical Research and the Altoona Arthritis and Osteoporosis Center, recently received the honor of being asked to be a part of a live national broadcast panel, according to a press release.
Six of these live national broadcasts were performed over two consecutive days from a studio based out of Fairfield, N.J. These broadcasts reached more than 3,000 attendees across the nation.
Kivitz, along with Dr. Roy Fleischmann from Texas and Dr. Peter Nash from Australia, were part of this national panel whose purpose was to introduce a new medication called RINVOQ.
RINVOQ was created by the pharmaceutical company AbbVie, and is a new therapy option for individuals who have moderate to severe rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.
During the clinical trials phase, when a new medication is being tested for approval by the FDA, the Altoona site was fortunate enough to be part of the process to conduct the clinical trials on this medication.
As a practicing physician, Kivitz has more than 37 years of experience treating patients with arthritis and rheumatic disorders. He received his medical degree from Albany Medical College in Albany, N.Y. He completed training in internal medicine at the North Shore University Hospital in Manhasset, N.Y., and Memorial Sloan Kettering Cancer Center in New York City. He then completed his fellowship training in rheumatology at Albany Medical College. He is board certified in internal medicine as well as the subspecialty of rheumatology.
Kivitz has authored and co-authored more than 500 research articles, abstracts and studies on subjects covering osteoarthritis, osteoporosis, rheumatoid arthritis and pain management. In addition, his studies have been published in several prestigious medical journals including The New England Journal of Medicine, Pain Medicine, Journal of the American Medical Association, Arthritis & Rheumatology and Journal of Clinical Rheumatology. He has served as a consultant on numerous osteoarthritis and rheumatoid arthritis clinical trials.
Kivitz is an active member of the Pennsylvania Medical Society and the American Medical Association. He holds certifications in Human Subjects Protection and HIPAA Research Training and is classified as a certified principal investigator by the Association of Clinical Research Professionals. His research work has focused on the development of newer strategies for treating patients with arthritis and rheumatic disorders. He has served as principal investigator or sub-investigator in more than 1,000 clinical trials.
